Yoshimi, Akihide
Lin, Kuan-Ting
Wiseman, Daniel H.
Rahman, Mohammad Alinoor
Pastore, Alessandro
Wang, Bo
Lee, Stanley Chun-Wei
Micol, Jean-Baptiste
Zhang, Xiao Jing
de Botton, Stephane
Penard-Lacronique, Virginie
Stein, Eytan M.
Cho, Hana
Miles, Rachel E.
Inoue, Daichi
Albrecht, Todd R.
Somervaille, Tim C. P.
Batta, Kiran
Amaral, Fabio
Simeoni, Fabrizio
Wilks, Deepti P.
Cargo, Catherine
Intlekofer, Andrew M.
Levine, Ross L.
Dvinge, Heidi
Bradley, Robert K.
Wagner, Eric J.
Krainer, Adrian R.
Abdel-Wahab, Omar
Article History
Received: 24 May 2018
Accepted: 28 August 2019
First Online: 2 October 2019
Competing interests
: A.M.I. has served as a consultant and advisory board member for Foundation Medicine. E.M.S. has served on advisory boards for Astellas Pharma, Daiichi Sankyo, Bayer, Novartis, Syros, Pfizer, PTC Therapeutics, AbbVie, Agios and Celgene and has received research support from Agios, Celgene, Syros and Bayer. R.L.L. is on the Supervisory Board of Qiagen and the Scientific Advisory Board of Loxo, reports receiving commercial research grants from Celgene, Roche and Prelude, has received honoraria from the speakers bureaus of Gilead and Lilly, has ownership interest (including stock and patents) in Qiagen and Loxo, and is a consultant and/or advisory board member for Novartis, Roche, Janssen, Celgene and Incyte. A.R.K. is a founder, director, advisor, stockholder and chair of the Scientific Advisory Board of Stoke Therapeutics and receives compensation from the company. A.R.K. is a paid consultant for Biogen; he is a member of the SABs of Skyhawk Therapeutics, Envisagenics BioAnalytics and Autoimmunity Biologic Solutions, and has received compensation from these companies in the form of stock. A.R.K. is a research collaborator of Ionis Pharmaceuticals and has received royalty income from Ionis through his employer, Cold Spring Harbor Laboratory. O.A.-W. has served as a consultant for H3 Biomedicine, Foundation Medicine, Merck and Janssen. O.A.-W. has received personal speaking fees from Daiichi Sankyo. O.A.-W. has received previous research funding from H3 Biomedicine unrelated to the current manuscript. D.I., R.K.B. and O.A.-W. are inventors on a provisional patent application (patent number FHCC.P0044US.P) applied for by Fred Hutchinson Cancer Research Center on the role of reactivating BRD9 expression in cancer by modulating aberrant <i>BRD9</i> splicing in <i>SF3B1</i> mutant cells.